These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32127832)

  • 41. Efficacy of Liraglutide in Non-Diabetic Obese Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Barboza JJ; Huamán MR; Melgar B; Diaz-Arocutipa C; Valenzuela-Rodriguez G; Hernandez AV
    J Clin Med; 2022 May; 11(11):. PubMed ID: 35683387
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.
    Torekov SS
    Cardiovasc Res; 2018 Aug; 114(10):e70-e71. PubMed ID: 30052921
    [No Abstract]   [Full Text] [Related]  

  • 43. Efficacy and safety of SGLT-2i in overweight/obese, non-diabetic individuals: a meta-analysis of randomized controlled trials.
    Shi Y; Si Y; Fu R; Zhang M; Jiang K; Dai W; Shen J; Li X; Yuan Y
    Endokrynol Pol; 2022; 73(1):71-80. PubMed ID: 35119088
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.
    Lean ME; Carraro R; Finer N; Hartvig H; Lindegaard ML; Rössner S; Van Gaal L; Astrup A;
    Int J Obes (Lond); 2014 May; 38(5):689-97. PubMed ID: 23942319
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice.
    Sauer N; Reining F; Schulze Zur Wiesch C; Burkhardt T; Aberle J
    Horm Metab Res; 2015 Jul; 47(8):560-4. PubMed ID: 25230325
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial.
    Wadden TA; Tronieri JS; Sugimoto D; Lund MT; Auerbach P; Jensen C; Rubino D
    Obesity (Silver Spring); 2020 Mar; 28(3):529-536. PubMed ID: 32090517
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysis.
    Ge JJ; Wang DJ; Song W; Shen SM; Ge WH
    J Endocrinol Invest; 2022 Feb; 45(2):261-273. PubMed ID: 34455568
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Liraglutide for the Treatment of Obesity: Analyzing Published Reviews.
    Pastor R; Tur JA
    Curr Pharm Des; 2019; 25(15):1783-1790. PubMed ID: 31267857
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).
    Femminella GD; Frangou E; Love SB; Busza G; Holmes C; Ritchie C; Lawrence R; McFarlane B; Tadros G; Ridha BH; Bannister C; Walker Z; Archer H; Coulthard E; Underwood BR; Prasanna A; Koranteng P; Karim S; Junaid K; McGuinness B; Nilforooshan R; Macharouthu A; Donaldson A; Thacker S; Russell G; Malik N; Mate V; Knight L; Kshemendran S; Harrison J; Hölscher C; Brooks DJ; Passmore AP; Ballard C; Edison P
    Trials; 2019 Apr; 20(1):191. PubMed ID: 30944040
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Liraglutide (Saxenda) for weight loss.
    Med Lett Drugs Ther; 2015 Jun; 57(1471):89-90. PubMed ID: 26079762
    [No Abstract]   [Full Text] [Related]  

  • 52. Pharmacological Treatment for Obesity in Adults: An Umbrella Review.
    Khalil H; Ellwood L; Lord H; Fernandez R
    Ann Pharmacother; 2020 Jul; 54(7):691-705. PubMed ID: 31958967
    [No Abstract]   [Full Text] [Related]  

  • 53. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
    Lau DCW; Erichsen L; Francisco AM; Satylganova A; le Roux CW; McGowan B; Pedersen SD; Pietiläinen KH; Rubino D; Batterham RL
    Lancet; 2021 Dec; 398(10317):2160-2172. PubMed ID: 34798060
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sodium-Glucose Co-Transporter-2 Inhibitors in Non-Diabetic Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis.
    Zheng H; Liu M; Li S; Shi Q; Zhang S; Zhou Y; Su N
    Front Endocrinol (Lausanne); 2021; 12():706914. PubMed ID: 34484120
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expert consensus on the use of liraglutide in the treatment of diabetes in internal medicine.
    Calvo Gómez C; Gómez-Huelgas R; Lima Ruiz J; Masmiquel Comas L; Michán Doña A; Zapatero Gaviria A
    Int J Clin Pharmacol Ther; 2016 Nov; 54(11):880-890. PubMed ID: 27487367
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomized controlled trial protocol of the cardiovascular safety and efficacy of liraglutide in the treatment of type 2 diabetes.
    Liang Y; Meng H; Li R; Yang J; Jia J; Hou Y
    Medicine (Baltimore); 2021 Jan; 100(3):e23948. PubMed ID: 33545972
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome.
    Papaetis GS; Filippou PK; Constantinidou KG; Stylianou CS
    Clin Drug Investig; 2020 Aug; 40(8):695-713. PubMed ID: 32583294
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes.
    Kim SH; Abbasi F; Lamendola C; Liu A; Ariel D; Schaaf P; Grove K; Tomasso V; Ochoa H; Liu YV; Chen YD; Reaven G
    Diabetes Care; 2013 Oct; 36(10):3276-82. PubMed ID: 23835684
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of subcutaneous semaglutide compared to placebo for weight loss in obese, non-diabetic adults: a systematic review & meta-analysis.
    Arastu N; Cummins O; Uribe W; Nemec EC
    Int J Clin Pharm; 2022 Aug; 44(4):852-859. PubMed ID: 35715543
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and efficacy of liraglutide on reducing visceral and ectopic fat in adults with or without type 2 diabetes mellitus: A systematic review and meta-analysis.
    He F; Chen W; Xu W; Liu D; Xiao Z; Tang Y; Lin Z; Liao Y; Bin J; Chen G; Chen Y
    Diabetes Obes Metab; 2023 Mar; 25(3):664-674. PubMed ID: 36314246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.